Thursday, August 22, 2013

MicuRx Finds $25M For Antiobiotic Development

Haywayrd-based biopharmaceutical firm MicuRx said this morning that it has raised $25M in a Series B funding. The company, which is developing antibiotics, said the funding was led by BVCF, and also included Morningside Group and Devon Park Bioventures. MicuRx said the funding will go to support development of an antibiotic targeting infections due to multi-drug resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Weixin Xu and Davis Yang of BVCF have both joined the company's board as part of the investment. More information »